The need for continuous cost-effectiveness analysis

At drug launch, treatments have some benefit and cost. However, drug prices may change over time. Additionally, treatment benefits may rise or fall depending on how well efficacy translates into effectiveness and how well physicians learn to manage adverse events. Mattingly and Love (2020) provide a case study of how cost-effectiveness analysis can change over…

Hepatitis C Around the World

The global burden of the hepatitis C virus (HCV) is distressing. “[A]n estimated 130–170 million persons (2%–3% of the world’s population) are living with hepatitis C virus (HCV) infection [1]. This infection, particularly in its chronic form, is associated with sizable morbidity and mortality. More than 350 000 deaths are attributed to HCV infection each…